Beigene-283 is primarily used in the development of targeted cancer therapies, particularly in the treatment of advanced solid tumors. It functions as a potent and selective inhibitor of specific kinase pathways involved in tumor growth and progression. Its application is notable in oncology research, where it demonstrates strong antitumor activity by blocking signaling proteins that drive cancer cell proliferation and survival. Due to its optimized pharmacokinetic profile, Beigene-283 is being evaluated in clinical trials for its efficacy in patients with resistant or refractory cancers, offering potential as part of precision medicine strategies. Its design allows for improved selectivity, reducing off-target effects and enhancing therapeutic outcomes.